Nanoparticle-based immunotherapy: state of the art and future perspectives.
Clicks: 259
ID: 105730
2020
: For several years now, medicine has been benefiting from the contribution of nanoparticles (NPs) technology for both diagnosis and therapy. They can be used as adjuvants, being capable of immune-modulating activity, or as carriers for molecules to be transported to a specific target, eventually loaded with specific ligands favoring specific uptake.: The review focuses on experimental use of NPs as adjuvants/carriers for allergen immunotherapy (AIT). Human clinical trials conducted so far are discussed.: Results of experimental studies and recent clinical trials support the use of NPs as carrier/adjuvant in AIT. Comparisons between NP-based and classical AIT are needed, to show the usefulness of the NP-based approach. However, there are still unsolved problems: the persistence of non-degradable NPs with possible toxicological consequences, and the formation of the protein corona around the NPs, which could alter their activity and fate. Virus-like particles seem the most promising NPs for allergy treatment, as for other vaccines. Over the next decade NP-based AIT will be largely used to treat allergic disorders.
| Reference Key |
di-gioacchino2020nanoparticlebasedexpert
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Di Gioacchino, Mario;Petrarca, Claudia;Gatta, Alessia;Scarano, Gilda;Farinelli, Anila;Della Valle, Loredana;Lumaca, Arianna;Del Biondo, Pietro;Paganelli, Roberto;Di Giampaolo, Luca; |
| Journal | expert review of clinical immunology |
| Year | 2020 |
| DOI | 10.1080/1744666X.2020.1762572 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.